Integra LifeSciences Holdings Corp. (NASDAQ:IART)’s share price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $87.08 and last traded at $86.41, with a volume of 68,087 shares trading hands. The stock had previously closed at $86.43.

Several brokerages recently weighed in on IART. Barclays PLC upped their price target on Integra LifeSciences Holdings Corp. from $74.00 to $77.00 and gave the stock an “equal weight” rating in a research note on Thursday, June 2nd. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Integra LifeSciences Holdings Corp. in a research note on Thursday, April 28th. Jefferies Group upped their price target on Integra LifeSciences Holdings Corp. from $81.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, July 29th. JPMorgan Chase & Co. began coverage on Integra LifeSciences Holdings Corp. in a research note on Wednesday, July 13th. They issued an “overweight” rating on the stock. Finally, Zacks Investment Research cut Integra LifeSciences Holdings Corp. from a “buy” rating to a “hold” rating in a research note on Wednesday, May 4th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $82.88.

The company has a market cap of $3.18 billion and a PE ratio of 351.78. The company has a 50 day moving average price of $82.64 and a 200-day moving average price of $72.18.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.76 by $0.03. The business had revenue of $249.30 million for the quarter, compared to the consensus estimate of $243.17 million. During the same period in the prior year, the business posted $0.79 earnings per share. Integra LifeSciences Holdings Corp.’s revenue was up 17.2% on a year-over-year basis. Equities analysts anticipate that Integra LifeSciences Holdings Corp. will post $3.48 EPS for the current year.

In other Integra LifeSciences Holdings Corp. news, CEO Peter J. Arduini sold 24,009 shares of Integra LifeSciences Holdings Corp. stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $84.52, for a total transaction of $2,029,240.68. Following the completion of the sale, the chief executive officer now directly owns 29,602 shares of the company’s stock, valued at approximately $2,501,961.04. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Richard D. Gorelick sold 4,000 shares of Integra LifeSciences Holdings Corp. stock in a transaction on Monday, August 1st. The shares were sold at an average price of $84.60, for a total value of $338,400.00. Following the sale, the vice president now directly owns 9,702 shares of the company’s stock, valued at $820,789.20. The disclosure for this sale can be found here.

Other large investors have recently modified their holdings of the company. Principal Financial Group Inc. raised its stake in shares of Integra LifeSciences Holdings Corp. by 7.0% in the fourth quarter. Principal Financial Group Inc. now owns 196,763 shares of the company’s stock worth $13,337,000 after buying an additional 12,904 shares during the period. Westfield Capital Management Co. LP raised its stake in shares of Integra LifeSciences Holdings Corp. by 41.7% in the fourth quarter. Westfield Capital Management Co. LP now owns 432,445 shares of the company’s stock worth $29,311,000 after buying an additional 127,170 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of Integra LifeSciences Holdings Corp. by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 928,232 shares of the company’s stock worth $62,916,000 after buying an additional 11,339 shares during the period.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.